Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The Peste des Petits Ruminants (PPR) vaccine developed by Middle East for Vaccines (MEVAC) is a veterinary vaccine indicated for the active immunization of small ruminants, specifically sheep and goats, against the Peste des Petits Ruminants virus (PPRV). PPR, also known as 'goat plague,' is a highly contagious viral disease characterized by severe pneumonia, fever, and mucosal erosions. The vaccine is a live-attenuated formulation, typically utilizing the Nigeria 75/1 strain, which is the international standard for PPR vaccination. It works by stimulating a robust and long-lasting immune response, providing protection against clinical disease and reducing viral shedding. This vaccine is a critical component of regional and global efforts to control and eventually eradicate PPR in endemic areas.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on peste des petits ruminants vaccine.